Nuzenio

Phase Iib

Phase Iib news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 10 latest news signals 8 publisher sources 100/100 entity strength

Latest news

Trevi Therapeutics Q2 Earnings Call Highlights - TradingViewTradingView · Fri, 07 Aug 2026 18:04:23 GMT NeuroThera Launches Phase IIb Trial at Yale for Novel Tourette Treatment - citybuzz -citybuzz - · Thu, 06 Aug 2026 00:24:05 GMT SciSparc (Nasdaq: SPRC) launches Phase IIb SCI-110 Tourette study - Stock TitanStock Titan · Wed, 05 Aug 2026 13:00:51 GMT NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-Its-Kind Treatment for Tourette Syndrome - Yahoo FinanceYahoo Finance · Wed, 05 Aug 2026 12:48:44 GMT SciSparc’s NeuroThera Opens Yale Site for Phase IIb SCI-110 Tourette Syndrome Trial - Quiver QuantitativeQuiver Quantitative · Wed, 05 Aug 2026 12:30:00 GMT Tourette drug candidate enters Phase IIb with prior 21% tic reduction - Stock TitanStock Titan · Wed, 05 Aug 2026 12:22:00 GMT Avere Therapeutics - The Pharma LetterThe Pharma Letter · Mon, 03 Aug 2026 15:34:12 GMT Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors for Huntington’s - Genetic Engineering and Biotechnology NewsGenetic Engineering and Biotechnology News · Fri, 31 Jul 2026 12:00:17 GMT

Timeline

Fri, 07 Aug 2026 18:04:23 GMTTrevi Therapeutics Q2 Earnings Call Highlights - TradingView

Thu, 06 Aug 2026 00:24:05 GMTNeuroThera Launches Phase IIb Trial at Yale for Novel Tourette Treatment - citybuzz -

Wed, 05 Aug 2026 13:00:51 GMTSciSparc (Nasdaq: SPRC) launches Phase IIb SCI-110 Tourette study - Stock Titan

Wed, 05 Aug 2026 12:48:44 GMTNeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-Its-Kind Treatment for Tourette Syndrome - Yahoo Finance

Wed, 05 Aug 2026 12:30:00 GMTSciSparc’s NeuroThera Opens Yale Site for Phase IIb SCI-110 Tourette Syndrome Trial - Quiver Quantitative

Wed, 05 Aug 2026 12:22:00 GMTTourette drug candidate enters Phase IIb with prior 21% tic reduction - Stock Titan

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

Phase IIb SCI4 live mentions Tourette3 live mentions Genetic Engineering3 live mentions Earnings Call Highlights2 live mentions NeuroThera Launches Phase2 live mentions IIb Trial2 live mentions Yale2 live mentions Novel Tourette Treatment2 live mentions SciSparc2 live mentions Nasdaq2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Phase Iib.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

8 distinct publisher/source names are currently connected to this entity page.